Torsade de Pointes Associated with the Use of Intravenous Haloperidol
Authors: Jeffrey L. Wilt
Journal: Annals of Internal Medicine (1993)

Brief Reports1 September 1993Torsade de Pointes Associated with the Use of Intravenous HaloperidolJeffrey L. Wilt, MD, Ann Mary Minnema, MD, Robert F. Johnson, MD, and Andrew M. Rosenblum, MDJeffrey L. Wilt, MDFrom St. Mary's Health Services and Blodgett Memorial Medical Center, Grand Rapids, Michigan., Ann Mary Minnema, MDFrom St. Mary's Health Services and Blodgett Memorial Medical Center, Grand Rapids, Michigan., Robert F. Johnson, MDFrom St. Mary's Health Services and Blodgett Memorial Medical Center, Grand Rapids, Michigan., and Andrew M. Rosenblum, MDFrom St. Mary's Health Services and Blodgett Memorial Medical Center, Grand Rapids, Michigan.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-5-199309010-00007 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Intensive-care-unit delirium requires rapid treatment to prevent morbidity [1]. Intravenous haloperidol (Haldol, McNeil Pharmaceuticals, Spring House, Pennsylvania) has been used frequently in recent years to combat intensive-care-unit delirium. Its advantages include minimal cardiac effects, even at doses greater than 100 mg/d [2]. We present four cases of haloperidol-associated torsade de pointes [3] developing in intubated patients with intensive-care-unit delirium.Case ReportsPatient 1A 39-year-old woman with bacterial meningitis developed acute congestive heart failure on hospital day 20 and required reintubation and intravenous haloperidol (5-mg increments) and lorazepam (Ativan, Wyeth-Ayerst Laboratories, Philadelphia, Pennsylvania) administration for sedation. Progressive Q-T interval widening was ...References1. Tesar GE, Stern TA. Rapid tranquilization of the agitated intensive care unit patient. Journal of Intensive Care Medicine. 1988; 3:195-201. Google Scholar2. Sanders KM, Minnema Am, Murray GB. Low incidence of extrapyramidal symptoms in treatment of delirium with intravenous haloperidol and lorazepam in the intensive care unit. Journal of Intensive Care Medicine. 1989; 4:201-4. Google Scholar3. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations, and a unifying hypothesis. Prog Cardiovasc Dis. 1988; 31:115-72. Google Scholar4. Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsade de Pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol. 1983; 2:806-17. Google Scholar5. Fowler NO, McCall D, Chou TC, Holmes JC, Hanenson IB. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol. 1976; 37:223-30. Google Scholar6. Laakso M, Aberg A, Savola J, Pentikainen PJ, Pyorala K. Diseases and drugs causing prolongation of the QT interval. Am J Cardiol. 1987; 59:862-5. Google Scholar7. Khan M, Logan KR, McComb JM, Adgey AA. Management of recurrent ventricular tachyarrhythmias associated with QT prolongation. Am J Cardiol. 1981; 47:1301-8. Google Scholar8. Zee-Cheng CS, Mueller CE, Seifert CF, Gibbs HR. Haloperidol and torsades de pointes (Letter). Ann Intern Med. 1985; 102:418. Google Scholar9. Fayer SA. Torsades de pointes ventricular tachyarrhythmia associated with haloperidol (Letter). J Clin Psychopharmacol. 1986; 6: 375-6. Google Scholar10. Kriwisky M, Perry GY, Tarchitsky D, Gutman Y, Kishon Y. Haloperidol-induced torsades de pointes. Chest. 1990; 98:482-4. Google Scholar Author, Article, and Disclosure InformationAuthors: Jeffrey L. Wilt, MD; Ann Mary Minnema, MD; Robert F. Johnson, MD; Andrew M. Rosenblum, MDAffiliations: From St. Mary's Health Services and Blodgett Memorial Medical Center, Grand Rapids, Michigan.Corresponding Author: Jeffrey L. Wilt, MD, Section of Pulmonary and Critical Care Medicine, P.O. Box 9166, West Virginia University, Morgantown, WV 26506-9166.Acknowledgments: The authors thank David Vidro for help with figure production and Dr. Angela Tiberio for help with manuscript preparation. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTraditional risk factors for QT interval prolongation and torsades de pointesIntravenous haloperidol: A systematic review of side effects and recommendations for clinical useOverdose of Cardiotoxic DrugsHaloperidol affects coupling between QT and RR intervals in guinea pig isolated heartValidation and Clinical Utility of the hERG IC50:C max Ratio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-AnalysisAcute Brain FailureAcquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivistPsychopharmacology in the Treatment of Patients with Cardiovascular DiseaseHaloperidolLorazepamReadings on Psychosomatic Medicine: Survey of Resources for TraineesPsychopharmacology in the Treatment of Patients with Cardiovascular DiseaseThe Brugada ECG and SchizophreniaDrug-induced long QT syndrome and fatal arrhythmias in the intensive care unitA Computerized Physician Order Entry Set Designed to Improve Safety of Intravenous Haloperidol UtilizationExamination of Baseline Risk Factors for QTc Interval Prolongation in Patients Prescribed Intravenous HaloperidolStatus Asthmaticus Complicated by Cardiac ArrestThe FDA extended warning for intravenous haloperidol and torsades de pointes: How should institutions respond?Prevention of Torsade de Pointes in Hospital SettingsPrevention of Torsade de Pointes in Hospital SettingsDrug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychoticsAntipsychoticsThe Combative PatientOverdose of Cardiotoxic DrugsDelirious PatientsThe Psychiatric Management of Patients with Cardiac DiseaseProarrhythmic Risk with Antipsychotic and Antidepressant DrugsA systematic review of cardiovascular effects after atypical antipsychotic medication overdoseDelirium in the Acute Care Setting: Characteristics, Diagnosis and TreatmentDeliriumDelirium in the Hospitalized Patient: A Primer for the Pharmacist ClinicianAntipsychotic AgentsPharmacologic Treatment of Acute Pediatric Methamphetamine ToxicityAntipsychotikainduzierte QT-VerlängerungAdverse Drug Reactions and Drug Interactions in the Intensive Care UnitTorsade de pointes induced by psychotropic drugs and the prevalence of its risk factorsAtypical AntipsychoticsSafety of medications used to treat acute agitationHaloperidol Decanoate 74050-97-8Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practiceSafety of droperidol in behavioural emergenciesInfluence of IV Haloperidol on Ventricular Repolarization and Monophasic Action Potential Duration in Anesthetized DogsPharmacology and pharmacokinetics of sedatives and analgesicsHaloperidol por vía intravenosa y torsade de pointesPharmacokinetic Factors in the Adverse Cardiovascular Effects of Antipsychotic DrugsTorsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for usePharmacological management of aggression and violenceTorsade de Pointes Due to Noncardiac DrugsDual Rate-dependent Cardiac Electrophysiologic Effects of Haloperidol: Slowing of Intraventricular Conduction and Lengthening of RepolarizationDroperidol, QT prolongation, and sudden death: What is the evidence?Antipsychotic AgentsConfusion and DeliriumEtiology and Management of DeliriumTorsade de Pointes Associated with the Administration of Intravenous HaloperidolPsychotropic drugs and the ECG: focus on the QTc intervalClinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adultThe Effect of Intravenous Haloperidol on QT Interval Dispersion in Critically Ill Patients: Comparison with QT Interval Prolongation for Assessment of Risk of Torsades de PointesThe Association Between Intravenous Haloperidol and Prolonged QT IntervalTiapride-induced torsade de pointesChemical restraintVentricular Ectopy Associated with Low-Dose Intravenous Haloperidol and Electroconvulsive TherapyCorrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromesDrug Interactions with CisaprideStudies on the Mechanism of a Fatal Clarithromycin-Pimozide Interaction in a Patient With Tourette SyndromeTorsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgeryMEDICAL ASSESSMENT OF PATIENTS PRESENTING WITH PSYCHIATRIC SYMPTOMS IN THE EMERGENCY SETTINGQuels sont les moyens?Comment évaluer le traitement ? Quels sont les éléments de choix d'un agent médicamenteux?Haloperidol, Midazolam and Intravenous SedationHaloperidol-Induced Torsade De PointesCardiotoxicity Associated with Use of Intravenous HaloperidolTorsade De Pointes Induced by Cisapride/Clarithromycin InteractionFREQUENTLY MISSED DIAGNOSIS IN GERIATRIC PSYCHIATRYPotassium, Antipsychotic Agents, Arrhythmias, and Sudden DeathSedation in the critically ill patientPsychosesTherapie von Risikopatienten mit NeuroleptikaTorsades de Pointes Associated With Intravenous Haloperidol in Critically Ill PatientsA Review of Erythromycin-Induced Malignant Tachyarrhythmia— Torsade de PointesTorsade de Pointes ventricular tachycardia, QT interval, and psychotropic drugsEffect of Ethanol, Haloperidol, and Lorezepam on Cardiac Conduction and ContractionDELIRIUMProbucol-associated tachyarrhythmic events and QT prolongation: Importance of genderSedation of the Agitated, Critically Ill Patient Without an Artificial AirwayUse of Haloperidol Infusions to Control Delirium in Critically Ill AdultsSedation during and after CPR-efforts: is it worth a guideline?Reversible QT Prolongation With Torsades De Pointes in a Patient With Pimozide IntoxicationMedical Disorders in the Schizophrenic PatientTorsade de pointes caused by high-dose intravenous haloperidol in cardiac patientsContinuous Droperidol Infusion for Management of Agitated Delirium in an Intensive Care UnitCardiotoxicity More Common in Thioridazine Overdose than with Other NeurolepticsImproving Patient Tolerance of Mechanical Ventilation: Challenges AheadRecent Advances in Critical CareAntipsychotic drugsConfusion and Delirium 1 September 1993Volume 119, Issue 5Page: 391-394KeywordsAtropineDeliriumDrugsHeart failureHypothyroidismIsoproterenolMagnesiumSedationThyroid-stimulating hormoneThyroxine ePublished: 15 August 2000 Issue Published: 1 September 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...